NAVANA PHARMACEUTICALS PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.2 BDT | +0.22% |
|
-8.89% | +9.24% |
Valuation
| Fiscal Period: June | 2023 |
|---|---|
| Capitalization 1 | 12,546 |
| Enterprise Value (EV) 1 | 16,267 |
| P/E ratio | 32.5 x |
| Yield | 1.11% |
| Capitalization / Revenue | 2.2 x |
| EV / Revenue | 2.85 x |
| EV / EBITDA | 18.4 x |
| EV / FCF | -6,738,086 x |
| FCF Yield | -0% |
| Price to Book | 2.87 x |
| Nbr of stocks (in thousands) | 107,416 |
| Reference price 2 | 116.8 |
| Announcement Date | 05/12/23 |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 3,149 | 3,607 | 4,759 | 5,706 |
| EBITDA 1 | 314.5 | 397.7 | 675.4 | 882.2 |
| EBIT 1 | 274.2 | 348.6 | 569.6 | 721.5 |
| Operating Margin | 8.71% | 9.67% | 11.97% | 12.64% |
| Earnings before Tax (EBT) 1 | 219.3 | 302.4 | 391.8 | 449.1 |
| Net income 1 | 137.4 | 202.3 | 274 | 356.9 |
| Net margin | 4.36% | 5.61% | 5.76% | 6.26% |
| EPS 2 | 1.713 | 2.521 | 3.415 | 3.590 |
| Free Cash Flow | - | -462.9 | -1,687 | -2,414 |
| FCF margin | - | -12.84% | -35.46% | -42.31% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | 1.100 | 1.300 |
| Announcement Date | 02/12/21 | 02/12/21 | 27/11/22 | 05/12/23 |
1BDT in Million2BDT
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 912 | 1,466 | 2,799 | 3,721 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.9 x | 3.685 x | 4.144 x | 4.217 x |
| Free Cash Flow | - | -463 | -1,687 | -2,414 |
| ROE (net income / shareholders' equity) | - | 6.32% | 8.07% | 9.09% |
| ROA (Net income/ Total Assets) | - | 4.51% | 5.8% | 5.41% |
| Assets 1 | - | 4,490 | 4,727 | 6,599 |
| Book Value Per Share 2 | 38.70 | 41.20 | 43.40 | 40.70 |
| Cash Flow per Share 2 | 0.6800 | 0.3200 | 0.8300 | 4.100 |
| Capex 1 | 19.7 | 522 | 1,198 | 1,598 |
| Capex / Sales | 0.63% | 14.47% | 25.17% | 28.01% |
| Announcement Date | 02/12/21 | 02/12/21 | 27/11/22 | 05/12/23 |
1BDT in Million2BDT
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +9.24% | 84.35M | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- NAVANAPHAR Stock
- Financials Navana Pharmaceuticals PLC
